Quality Home Health Care, Llc | |
3675 West Outer Rd, Suite 203-b, Arnold, Missouri 63010 | |
(314) 200-9905 | |
Name | Quality Home Health Care, Llc |
---|---|
Location | 3675 West Outer Rd, Suite 203-b, Arnold, Missouri |
Certified By | Medicare |
Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
Medicare ID | 267628 |
Ownership Type | Proprietary |
Service Area Zip Codes | 63005, 63011, 63012, 63016, 63017, 63019, 63020, 63021, 63026, 63028, 63031, 63033, 63042, 63043, 63050, 63051, 63052, 63088, 63101, 63103, 63104, 63106, 63107, 63108, 63109, 63110, 63111, 63112, 63113, 63114, 63115, 63116, 63118, 63121, 63122, 63123, 63124, 63125, 63128, 63129, 63130, 63131, 63132, 63133, 63135, 63136, 63137, 63138, 63139, 63144, 63146, 63147, 63301, 63303, 63304, 63348, 63366, 63368, 63376 |
NPI Number | 1811284110 |
Organization Name | QUALITY HOME HEALTH CARE LLC |
Address | 3675 West Outer Road Suite 203 B, Arnold, MO 63010 |
Phone Number | 314-200-9905 |
News Archive
Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Lupin Limited submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Ranexa® (ranolazine extended-release tablets).
For the study lead researcher Dr. Graeme Zosky a research fellow at the Telethon Institute for Child Health Research in Subiaco, WA, compared two-week-old mice with vitamin D deficiency to normal mice. He noted that mice with a vitamin D deficiency had weaker lungs and that the difference was substantial.
Medivir AB, the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe.
Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).
A University of Texas at Arlington team exploring how neuron growth can be controlled in the lab and, possibly, in the human body has published a new paper in Nature Scientific Reports on how fluid flow could play a significant role.
› Verified 3 days ago
Quality Rating: |
News Archive
Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Lupin Limited submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Ranexa® (ranolazine extended-release tablets).
For the study lead researcher Dr. Graeme Zosky a research fellow at the Telethon Institute for Child Health Research in Subiaco, WA, compared two-week-old mice with vitamin D deficiency to normal mice. He noted that mice with a vitamin D deficiency had weaker lungs and that the difference was substantial.
Medivir AB, the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe.
Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).
A University of Texas at Arlington team exploring how neuron growth can be controlled in the lab and, possibly, in the human body has published a new paper in Nature Scientific Reports on how fluid flow could play a significant role.
› Verified 3 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often the home health team began their patients’ care in a timely manner | 100 | 95.7 |
How often the home health team taught patients (or their family caregivers) about their drugs | 100 | 98.6 |
How often the home health team checked patients’ risk of falling | 100 | 99.6 |
How often the home health team checked patients for depression | 100 | 97.4 |
How often the home health team made sure that their patients have received a flu shot for the current flu season. | 81.7 | 78.7 |
How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 83.8 | 82.2 |
With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 100 | 96.4 |
News Archive
Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Lupin Limited submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Ranexa® (ranolazine extended-release tablets).
For the study lead researcher Dr. Graeme Zosky a research fellow at the Telethon Institute for Child Health Research in Subiaco, WA, compared two-week-old mice with vitamin D deficiency to normal mice. He noted that mice with a vitamin D deficiency had weaker lungs and that the difference was substantial.
Medivir AB, the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe.
Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).
A University of Texas at Arlington team exploring how neuron growth can be controlled in the lab and, possibly, in the human body has published a new paper in Nature Scientific Reports on how fluid flow could play a significant role.
› Verified 3 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often patients got better at walking or moving around | 86 | 79.6 |
How often patients got better at getting in and out of bed | 81.3 | 81.1 |
How often patients got better at bathing | 89.4 | 82.3 |
How often patients’ breathing improved | 88.9 | 82.8 |
How often patients’ wounds improved or healed after an operation | - | 92.3 |
How often patients got better at taking their drugs correctly by mouth | 86.1 | 75 |
How often home health patients had to be admitted to the hospital | 15.6 | 15.4 |
How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 7 | 13 |
How often physician-recommended actions to address medication issues were completely timely | 100 | 94 |
News Archive
Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Lupin Limited submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Ranexa® (ranolazine extended-release tablets).
For the study lead researcher Dr. Graeme Zosky a research fellow at the Telethon Institute for Child Health Research in Subiaco, WA, compared two-week-old mice with vitamin D deficiency to normal mice. He noted that mice with a vitamin D deficiency had weaker lungs and that the difference was substantial.
Medivir AB, the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe.
Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).
A University of Texas at Arlington team exploring how neuron growth can be controlled in the lab and, possibly, in the human body has published a new paper in Nature Scientific Reports on how fluid flow could play a significant role.
› Verified 3 days ago
Question Type: | Rating by Patients |
---|---|
Health team gave care in a professional way | Not Available |
Health team communicated well with them | Not Available |
Health team discussed medicines, pain, and home safety | Not Available |
How patients rated overall care from agency | Not Available |
News Archive
Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Lupin Limited submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Ranexa® (ranolazine extended-release tablets).
For the study lead researcher Dr. Graeme Zosky a research fellow at the Telethon Institute for Child Health Research in Subiaco, WA, compared two-week-old mice with vitamin D deficiency to normal mice. He noted that mice with a vitamin D deficiency had weaker lungs and that the difference was substantial.
Medivir AB, the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe.
Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).
A University of Texas at Arlington team exploring how neuron growth can be controlled in the lab and, possibly, in the human body has published a new paper in Nature Scientific Reports on how fluid flow could play a significant role.
› Verified 3 days ago
The patient survey data of Quality Home Health Care, Llc is compared against the national average with the color code indicators: Better than National Average Worse than National AverageExperience Measure | Provider | National Avg. |
---|---|---|
Percent of patients who reported that their home health team gave care in a professional way | 90 | 88 |
Percent of patients who reported that their home health team communicated well with them | 87 | 85 |
Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 78 | 83 |
Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 71 | 84 |
Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 47 | 78 |
News Archive
Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Lupin Limited submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Ranexa® (ranolazine extended-release tablets).
For the study lead researcher Dr. Graeme Zosky a research fellow at the Telethon Institute for Child Health Research in Subiaco, WA, compared two-week-old mice with vitamin D deficiency to normal mice. He noted that mice with a vitamin D deficiency had weaker lungs and that the difference was substantial.
Medivir AB, the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe.
Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).
A University of Texas at Arlington team exploring how neuron growth can be controlled in the lab and, possibly, in the human body has published a new paper in Nature Scientific Reports on how fluid flow could play a significant role.
› Verified 3 days ago
Quality Home Health Care, Llc Location: 3675 West Outer Rd, Suite 203-b, Arnold, Missouri 63010 Ratings: Phone: (314) 200-9905 |